文献速递膀胱癌与上尿路尿路上皮癌

顺铂不耐受肌层浸润性膀胱癌患者立即根治性膀胱切除术后长期生存差

Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy.
PubMed 文献 · BJU Int · 2025-09-11

该多中心回顾性研究比较了顺铂不耐受与顺铂耐受的肌层浸润性膀胱癌患者接受立即根治性膀胱切除术后的生存结局,并以SWOG-8710试验的顺铂耐受患者作为外部对照。结果显示顺铂不耐受组中位无事件生存期12.1个月、中位总生存期14.5个月,均显著劣于顺铂耐受组(分别为28.8和60.1个月,P<0.001),且死亡多与非癌症原因相关。

要点

  • 顺铂不耐受MIBC患者IRC后中位OS仅14.5个月,长期生存差。
  • 顺铂不耐受组中位EFS 12.1个月,显著劣于顺铂耐受组的28.8个月。
  • 死亡多与非癌症原因相关,提示需关注非肿瘤性合并症管理。

核心结论

  • 顺铂不耐受MIBC患者接受IRC后预后差,中位OS为14.5个月(95%CI 11.1-17.9),死亡主要与非癌症原因相关。
  • 该结果可为探索新型药物或替代化疗方案的临床试验提供基准。

研究设计与样本

  • 回顾性分析2006至2021年美国四家三级中心接受IRC的cT2-4cN0-1M0 MIBC患者数据。
  • 共纳入379例顺铂不耐受患者和125例顺铂耐受患者。
  • 生存分析采用Kaplan-Meier法和log-rank检验,并与SWOG-8710试验的顺铂耐受患者进行外部比较。

主要发现

  • 顺铂不耐受组中44.8%为cT3/4,顺铂耐受组为60%。
  • 顺铂不耐受组83.3%死亡,顺铂耐受组79.2%死亡。
  • 顺铂不耐受组中位EFS和OS分别为12.1和14.5个月,顺铂耐受组分别为28.8和60.1个月(P<0.001)。

临床怎么用

  • 顺铂不耐受MIBC患者行IRC后生存预期差,应充分告知预后并考虑临床试验。
  • 需重视非癌症死亡原因,加强围手术期及术后合并症管理。

局限性

  • 回顾性比较当代多中心数据与随机对照试验数据存在固有局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare survival and oncological outcomes of cisplatin-ineligible patients (Cis-I) and cisplatin-eligible (Cis-E) patients with muscle-invasive bladder cancer (MIBC) undergoing immediate radical cystectomy (IRC), as IRC is currently considered the standard-of-care for Cis-I patients with MIBC. PATIENTS AND METHODS: Data from patients with clinical (c)T2-4cN0-1M0 MIBC undergoing IRC, between 2006 and 2021, were retrospectively analysed from four tertiary care centres in the United States. Overall, recurrence-free and event-free survival were described using the Kaplan-Meier method and tested using the log-rank test. For context, we compared survival outcomes against those in Cis-E patients with MIBC undergoing IRC from the Southwest Oncology Group (SWOG)-8710 trial. RESULTS: Overall, 379 Cis-I and 125 Cis-E patients with cT2-4cN0-1M0 MIBC who underwent IRC were included. Cis-I patients included 44.8% cT3/4 vs 60% cT3/4 in the Cis-E group. Overall, 83.3% of Cis-I and 79.2% of Cis-E patients died during follow-up. The median event-free and overall survival were 12.1 and 14.5 months for the Cis-I group and 28.8 and 60.1 months for the Cis-E group (P < 0.001). [Correction added on 10 October 2025, after first online publication: The preceding sentence has been revised in this version.] Limitations include retrospective comparison of contemporary multi-institutional data with that of a randomised control trial. CONCLUSIONS: The Cis-I patients with MIBC undergoing IRC fared poorly, with a median overall survival of 14.5 (95% confidence interval 11.1-17.9) months, mostly due to non-cancer-related deaths. These results provide a benchmark for clinical trials exploring novel agents or alternative chemotherapy regimens in Cis-I patients with MIBC.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Fazili A, Jazayeri SB, Rose KM, et al. Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy. BJU Int. 2025. PMID: 40932312. doi:10.1111/bju.16895

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。